Discussion  by unknown
contrary, the distributions of local recurrence were similar
between the groups, with only a slight difference in terms
of distant recurrence. The disease-free survival did not
show a significant difference between the groups, and
a more detailed analysis showed that overall survival of
patients undergoing isolated PA reconstruction was
mainly affected by nonneoplastic events. This finding
was confirmed by univariate and multivariate analyses
of disease-free survival.
Overall, PA reconstruction in patients with NSCLC not
only is feasible and safe but yields excellent long-term sur-
vival. Our results support this technique as a viable and on-
cologically effective option for patients with NSCLC.
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SDiscussion
Dr Shaf Keshavjee (Toronto, Ontario, Canada). Federico, I
congratulate you and your team on an excellent report of more
than 100 sleeve resections of the PA with an operative mortality
as good as or better than most report with simple lobectomy.
First, would you discuss a little further why you think the pa-
tients with isolated PA resections did worse than those with com-
bined bronchovascular resections? The 5-year survival was
actually half.
Dr Venuta. Thank you for your comments. When this point
emerged from the statistical analysis, it really surprised us. We
were more than just surprised, we were disappointed. In fact, we
feared that this assumption would again open the door to the sup-
porters of pneumonectomy, who believe that the closer we go to
the hilum, the better we clean the lymphatic drainage and the higher
will be long-term survival. We have also, however, done a disease-
free survival analysis. That disease-free survival is NSCLC-specific
survival and shows no significant differences between the groups.
These groups show exactly the same incidences of local and distant
recurrence. The differences in overall survival between the groups
were probably related to the numbers of nonneoplastic events,
which were higher in the isolated PA reconstruction population.
Dr Keshavjee.My second question is with respect to oncologic
considerations. If you see tumor transgressing the PA wall, that is
intraluminally, are you more likely to recommend adjuvant chemo-
therapy for distant disease concerns?
Dr Venuta. Full-thickness invasion of the vascular wall with tu-
mor inside the artery was extremely rare in our experience. I can
clearly remember only 1 patient with a tumor inside the lumen.
That patient also had N1 disease and received adjuvant chemother-
apy. e believe that this is a rare event that should be addressed on
a case-by-case basis with the medical and radiation oncologists.
DrKeshavjee. Finally, in terms of your decision making, for the
patients who might get induction chemotherapy, do you operate to
resect the PA on the basis of the original CT findings, or do yougery c November 2009
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Smake your decision to resect the PA intraoperatively on the basis of
current findings?
Dr Venuta. The original CT findings certainly give good infor-
mation about the previous extent of the disease. What we observe
on the operating table is much more important, however, and the
final decision is made on the basis of these findings.
Dr Mark Krasna (Towson, Md). Dr Venuta, excellent presen-
tation, and we owe you and Dr Rendina a debt in terms of using
this technique in our practice.
I have two specific questions. First, you talked about induction
therapy. Did any of your patients receive chemotherapy with radi-
ation and then PA resection, or were these cases induction with che-
motherapy alone?
Dr Venuta. Our standard policy is to administer induction che-
motherapy. All patients in this group received induction chemo-
therapy, with the exception of 3 who received radiotherapy.
Those 3 patients received induction radiotherapy because their dis-
ease had been judged inoperable at other institutions, and the radio-
therapy was actually administered with therapeutic intent. After our
evaluation, these cases were judged operable.
Dr Krasna. And there was no difference between those 3 and
the others?
DrVenuta. Those 3 were the 3 who underwent pneumonectomy
under CPB with patch reconstruction of the origin of the left PA.
Dr Krasna. My other question is related to another technique
that you and Dr Rendina have helped us with, which is routine
use of the intercostal muscle flap. As you know, we do that after
all chemoradiation resections. In my personal practice, I always
use the flap as a circumferential wrap when I do the bronchial
sleeve. I’m curious, if you’re doing a bronchial and arterial sleeve,
how do you actually place your intercostal flap?
Dr Venuta. The intercostal flap is always used in case of com-
bined bronchovascular reconstruction, and the flap is wrapped
around the bronchus with the technique that we have previously de-
scribed for isolated bronchial sleeve resection. In such cases, we
just pay a little more attention when we pass it between the bron-
chus and the artery.
Dr Robert J. Cerfolio (Birmingham, Ala). I congratulate you
and Dr Rendina. You talked to me about some of the finer tech-
niques of PA resection, and I took those back to Birmingham and
have been able to do them, though probably not as well as you. I
was a little disappointed that you didn’t have more of the actual sur-
gical techniques, because that is the key to this.
I have a couple of quick questions. One of the things you’ve
done is, instead of clamping the PA distally, you have movedThe Journal of Thoracic and Carthat clamp to the inferior pulmonary vein if you’re doing a left up-
per lobe vein. Are you still doing that? Your distal control of the
artery is really the vein, allowing you to have a lot of room to
work in the PA, correct?
Dr Venuta. Recently we moved to the control of the distal PA at
the hilum, if there is enough space to place the clamp. Otherwise,
we keep on clamping the inferior vein.
Dr Cerfolio. Well, I love the fact that you taught me how to
clamp the vein. It allows me to look inside the artery. It allows
me to judge whether there’s tension on the artery. Instead of work-
ing in a tiny little area in between the artery with a proximal clamp
and a distal clamp right next to it, I’ve got the whole PA wide open
and more room and better ability to judge whether I needed to
patch or do an end-to-end anastomosis. So I think that’s a great
trick.
Dr Venuta. That is obviously done when it’s possible and there
is room to place a clamp. If this is not possible, we are forced to go
down to the inferior vein.
Dr Cerfolio. Okay. The second thing is heparin. I have moved
away now to using almost no intraoperative heparin. I mean that I
will give them 500 units of heparin just to treat ‘‘the lawyers,’’ in
case there’s a clot in the PA, but I don’t know whether we really
need heparin. Are you heparinizing when you clamp your PA?
Dr Venuta.We use much less heparin than we did before. Now
we use between 1500 and 2000 units before clamping. We still
don’t reverse heparin with protamine at the end of the operation,
and these patients receive standard antithrombotic prevention
with low–molecular weight subcutaneous heparin, as do all the
other patients.
Dr Cerfolio. I’m surprised to hear you say that you wrap the
bronchus. I never circumferentially wrap the bronchus. I just put
it around the top part of the bronchus. So when I do a PA sleeve
with a sleeve of the bronchus and a sleeve of the PA, I just put
them in between. Are you really circumferentially wrapping the
bronchus or the PA, or just interposing them in between?
Dr Venuta. We wrap the bronchus with the intercostal muscle.
In our early studies, we demonstrated that intercostal wrapping con-
tributes to protecting the bronchial anastomosis and separating the
potential dehiscence from the rest of the pleural cavity, avoiding
bronchopleural or bronchoarterial fistulas. It also contributes to re-
vascularization of the bronchus, and this has been demonstrated
with arteriography.
Dr Cerfolio. So obviously since I got every question wrong and
you are doing it quite differently from me, I need some more help
and learning from you and your group. Thank you.diovascular Surgery c Volume 138, Number 5 1191
